One of the earliest events in epithelial carcinogenesis is the dissolution of tight junctions (TJ) and cell polarity signals that are essential for normal epithelial barrier function. Here we report that EFA6B, a guanine nucleotide exchange factor for the Ras superfamily protein Arf6 that helps assemble and stabilize TJ, is required to maintain apico-basal cell polarity and mesenchymal phenotypes in mammary epithelial cells. In organotypic 3D cell cultures, endogenous levels of EFA6B were critical to determine epithelial-mesenchymal status.
Introduction
Gene expression profiling has helped define five intrinsic tumor subtypes; essentially based on the expression of the two hormonal receptors, estrogen (ER) and progesterone receptor (PR), and HER2. The triple-negative breast cancer (TNBC) subtype does not express any of these receptors rendering it unsuitable for the hormonal and anti-HER2 treatments (1) .
TNBC is associated with low overall survival and high recurrence. Transcriptomic analyses have identified a new BC subtype with poor prognosis named claudin-low (Cld-low), defined by the loss of expression of the proteins constitutive of the tight junction (TJ) (2, 3) . This subtype, which represents 12% of total BC, is 75% TNBC, characterized by a core epithelialto-mesenchymal transition (EMT) signature, and enriched in cancer stem cells (CSC), which are associated with relative resistance to conventional anti-cancer treatments.
We have reported that EFA6 (Exchange Factor for Arf6) contributes to the assembly and maintenance of the TJ in the canine kidney cell line MDCK (4, 5) . Four isoforms of EFA6 (A, B, C, D) are encoded by separate genes (PSD, PSD4, PSD2, PSD3, respectively).
EFA6A, B and D have ubiquitous expression while EFA6C is restricted to neuronal cells. We found that EFA6B levels increase at newly-formed cell-cell contacts during epithelial polarity development to help promote TJ assembly (4, 5) . Once TJs are assembled, the levels of EFA6B decreases, yet at steady-state EFA6B still contributes to stabilize the TJs. Knockdown of EFA6B is sufficient to impair the assembly and stability of the TJs (5) . Hence, the regulation of the levels of EFA6B proteins is key to TJ homeostasis.
In the present study, we have asked whether the EFA6B protein could act as an antagonist to malignant progression. To answer this question we combined in vivo expression analyses in human breast tumor samples with in vitro approaches. Based on our results, we 5 propose that EFA6B acts as an antagonist at the early stages of breast cancer development by hampering TJ disassembly and loss of epithelial polarity. 
Materials and Methods
Cells. MCF7, T47D, SKBR3 and MCF10A cells were obtained from the ATCC, authenticated by short tandem repeat profiling by the vendor and passaged for fewer than 6 months prior to experiments. Cells were grown in DMEM containing 10% FCS, except MCF10A cells grown in DMEM-F12, 5% horse serum, insulin, hydrocortisone, EGF, cholera toxin (6) . Transient transfection was performed by nucleofection (AMAXA), stable transfection by lipofection using JETPEI (Polyplus Transfection). For stable expression of EFA6Bvsvg, cells were selected with geneticin (Invitrogen) two days after transfection and low expressor clones were isolated. They all gave similar results in 2D and 3D-culture assays.
One clone was used in all the assays, and two other clones when randomly used in the different assays displayed similar results. When indicated cells were grown on permeable filters (Costar) at 3x10 5 cells/12mm filter. For 3D-cell culture, 2x10 3 cells were mixed with 25µl of Matrigel (BD Biosciences) deposited as a drop on a 12mm glass coverslip. MDCKEFA6Bvsvg cells were described elsewhere (5) . Prior to TGFß treatment the cells were serum starved overnight and 10µg/ml TGFß (Sigma-Aldrich) added for the indicated period of times.
DNA, siRNAs, shRNAs. pEGFP-Arf6T27N and pcDNA3-EFA6Bvsvg were described elsewhere (7, 8) . EFA6B was cloned into pEGFPC3 by PCR. The silencing mutations to generate a construct insensitive to the siRNAs were introduced using the QuickChange mutagenesis kit (Agilent Technologies). Extinction of EFA6B expression was obtained in MCF7 cells using a pool of 4 siRNA or in MCF10A, T47D and SKNBR3 cells using a pool of three human EFA6B specific shRNA cloned into the lentiviral vector pLB, independently expressing GFP (Addgene, #11619). Sequences of all the primers, siRNAs and shRNAs are 7 described in the Supplementary Methods. The pWZL-Blast-mouse-E-cadherin lentiviral vector was obtained from Addgene (#18804) (9) .
Antibodies. Rabbit polyclonal sera specific for ZO-1, claudin-1, occludin (Invitrogen), EFA6B (Sigma-Aldrich), Smad2, phospho-Smad2 (Ser465/467) (Cell Signaling), mouse monoclonals specific for E-cadherin, ß-catenin, GM130 (BD Biosciences), RhoA (Santa Cruz Biotechnology), actin, vsvg tag (Sigma-Aldrich), rabbit monoclonal specific for phosphoEzrin/Radixin/Moesin (Cell Signaling). The mouse monoclonal anti-Arf6 was described elsewhere (10) .
Transepithelial Electrical Resistance (TER). The TER was measured with an EVOM
(WPI) using triplicates or quadruplicates for each measurement as previously described (11) .
Immunofluorescence. Cells were fixed in PFA, the samples processed as previously described (4) and imaged on a confocal microscope (Leica TCS-SP5). TJ length and fluorescence intensity quantifications were performed based on the occludin fluorescence staining using a home-made ImageJ program described in details in the Supplementary Methods (12).
Immunoblot. Cells were solubilized in SDS lysis buffer and the lysates prepared for immunoblot as previously described (5) . The proteins were revealed by chemiluminescence (Amersham) and the membranes analyzed with the luminescent analyzer LAS-3000 (Fujifilm). 
Results

Exogenous expression of EFA6B in MCF7 cells restores a normal polarized epithelial monolayer with functional TJ
To address the role of EFA6B on BC development, we first asked whether the exogenous expression of EFA6B would enable tumoral mammary cells to assemble a functional TJ. We chose to study the MCF7 cells because it is the only human mammary tumoral cell line known to assemble, although very partially, a TJ. Owing to their weakly tumoral phenotype they adopt an incomplete polarized morphology when grown on filters and an unpolarized compact cell cluster organization under 3D-culture conditions (14, 15) . After stable transfection of EFA6Bvsvg we selected subclones with no more than 5 times the level of the endogenous protein (Fig. 1B) . At this level of expression, EFA6Bvsvg remained localized at the apical pole of the cells consistent with our previous observations for the endogenous protein in MDCK cells (Fig. 1A) (4) . When grown to confluence on filters about 10% of MCF7 cells organized in small patches of 5-10 cells assembled a TJ. In contrast, MCF7 cells expressing EFA6Bvsvg (MCF7-EFA6Bvsvg) demonstrated consistent assembly of a continuous TJ throughout the entire monolayer. The AJs correctly assembled and were not affected by EFA6Bvsvg expression (Fig. 1A and Supplementary Fig. S1A-B) . The expression of EFA6Bvsvg did not alter the levels of expression of the components of the TJ, nor those of the AJ, nor the substrate of EFA6B, Arf6 (Fig. 1B ). An automated quantification based on occludin staining showed that TJ size and mean intensity increased at least 3 and 4 times, respectively (Fig. 1C) . The assembled TJs were functional as MCF7-EFA6Bvsvg gained trans-epithelial resistance (TER) faster than control cells with a 3.2-fold increase at day 3 ( Fig. 1D ). More strikingly, the MCF7-EFA6Bvsvg cells adopted characteristics of a well- (Fig. 1A and Supplementary Fig. S1A-B) . In contrast, MCF7 cells displayed a heterogeneous and rather round morphology, tended to form multilayers, displayed a continuous plasma membrane staining of the AJs all around the cell, and formed little TJs and no microvilli ( Fig. 1A and Supplementary Fig. S1A-B) . Thus, expression of facing the lumen displayed a strong actin staining co-labeled for the apical phosphorylated proteins of the ERM family ( Fig. 1E and Supplementary Fig. S1C-D) . The AJ proteins were restricted to the lateral surface and the TJ markers confined to the apex of the lateral membrane delineating the apical domain ( Fig. 1E and Supplementary Fig. S1C-D) . Finally, the Golgi apparatus was positioned above the nucleus, consistent with the correct orientation of the apico-basal axis ( Supplementary Fig. S1D ). Thus, EFA6Bvsvg expression is not only capable of facilitating the assembly of the TJ, it also promotes the reversion to an epithelial phenotype resulting in cells organizing collectively into normal mammary acini-like structures. This property was totally blocked upon co-expression of the dominant negative Arf6T27N-GFP (Fig. 1G ), indicating that EFA6B effects are dependent on Arf6 activation.
EFA6B contributes to the formation and fusion of VACs to generate lumens in polarized
MCF7 acini
Although, MCF7 cells do not form acinis, they do form aggregates indicating that the limiting step to make normal acinis is likely the ability to form lumens. Thus, we investigated how MCF7-EFA6Bvsvg contained 3 times more VACs and 5 times more lumens than control MCF7 cells (Fig. 2F ). The lumens formed in MCF7-EFA6Bvsvg cells displayed the typical characteristics of an apical plasma membrane with actin-rich microvilli, selective staining for apical markers such as the P-ERM proteins (Fig. 2B) , absence of the basolateral proteins ß-catenin and E-cadherin ( Fig. 2B-C ) and surrounded by a TJ ring (Fig. 2C) . To assess EFA6B localization during luminogenesis we generated a stable MCF7 cell line expressing EFA6BGFP. Interestingly, at early stages EFA6BGFP was found at the cell surface, then on the VACs and at the apical plasma membrane (Fig. 2D) . To confirm that the lumens were formed by fusion of the VACs with the plasma membrane we mixed MCF7-EFA6BGFP and MCF7 control cells. We observed that whole lumens stained for F-actin and P-ERM were made of one half labeled with EFA6BGFP and the other half unlabeled. Thus, upon fusion the VACs provide one half of the lumen, the other half being formed on the other side by the facing cell (Fig. 2E) . Also, upon fusion of the VACs, the new lumens were rapidly limited to the cell-cell contact by a ring of TJ (Fig. 2E ).
Wild-type MCF7 cells form typical VACs and small lumens albeit essentially seen in between two cells (Fig. 1F and Supplementary Fig. S1E ). We asked whether the endogenous EFA6B was also necessary to generate these VACs and small lumens. We used a pool of four siRNAs that specifically downregulated EFA6B but not the other EFA6 isoforms expressed in MCF7 cells, EFA6A and EFA6D ( Supplementary Fig. S2A-B) . We observed that siRNA knockdown of EFA6B led to half fewer VACs and 3 times less lumens (Fig. 2G) .
Collectively, our results showed that EF6AB is involved in the formation and fusion of the VACs to form lumens within MCF7 cell aggregates, providing a mechanistic explanation as to how EFA6B contributes to the epithelial phenotypic reversion of MCF7 cells in 3D-culture. 
EFA6B repression in MCF7 cells abrogates the assembly of TJs and leads to highly unorganized aggregates
Next, we anayzed the effects of EFA6B downregulation by siRNA. When grown on filters, EFA6B-depleted cells displayed a less organized phenotype with a higher propensity to form multilayers. No TJ formation was observed, although the AJ was unaffected as well as the total amount of TJ proteins (Fig. 3A-C) , indicating that EFA6B is regulating the TJ assembly per se as previously observed in MDCK cells (4, 5) . When grown in Matrigel, the aggregates became much less compact and appeared multi-lobular reminiscent of the "grape-like" morphotype typically found in advanced tumoral cell lines (14, 15) . In these unorganized aggregates, AJ staining was still visible while the TJ and the apical membrane domain were absent (Fig. 3D) . The proportion of grape-like aggregates was reduced upon EFA6Bvsvg expression and increased in EFA6B knock-down cells. As a consequence, the percentage of aggregates with lumen(s) was proportionally reduced in EFA6B knock-down cells (Fig. 3E-F ). The specificity of EFA6B knock-down was verified by a rescue experiment in which the effects of the depletion of the endogenous EFA6B protein by siRNA were reverted by the coexpression of a siRNA-insensitive EFA6B construct ( Supplementary Fig. S2C-D) . In conclusion, while overexpression of EFA6B supports the epithelial phenotype, downregulation of endogenous EFA6B promotes the mesenchymal phenotype.
EFA6B repression disturbs the epithelial phenotype of MCF10A, T47D and SKBR3/Ecadherin cells
We then assessed the effects of EFA6B depletion on the collective organization of other (Fig. 4A-C) . At later stages, EFA6B depletion did not prevent the cells from eventually forming a single central lumen, most likely because MCF10A cells do not form their lumen by exocytosis of VACs, but by cavitation a process dependent on apoptosis (19), which we found not to be affected by EFA6B levels of expression (data not shown). Next, we studied the T47D cell line which is similar to MCF7 (ER/PR+, HER2-low) with an intermediate epithelial-mesenchymal phenotype although they do not assemble any TJ. As previously reported (14, 15) , T47D
wild-type as well as pLB-transduced cells adopted the "mass" phenotype. Similarly to MCF7, upon depletion of EFA6B, T47D cells no longer formed round and compact aggregates but rather unorganized loose structures (Fig. 4D-F) . Subsequently, we studied the more tumoral cell line SKBR3 (ER/PR-, HER2-high) that does not express E-cadherin and organizes as archetypical grape-like structure (14, 15) . However, upon exogenous expression of Ecadherin, SKBR3 cells were shown to organize in the "mass" phenotype ( (20) and Fig. 4G-I ).
While knock-down of EFA6B in SKBR3 cells did not affect their grape-like phenotype (data not shown), EFA6B knocked-down in SKBR3/E-cadherin cells reverted the "mass" phenotype back to a grape-like phenotype. This result supports our previous observations that EFA6B acts downstream of E-cadherin to regulate the TJ assembly and epithelial cell polarization (4, 5) . Altogether, our results demonstrate that EFA6B expression is required for the proper collective organization of mammary epithelial cells.
Exogenous expression of EFA6Bvsvg abrogates the TGFß-induced EMT
We showed that increasing EFA6Bvsvg expression supports the epithelial phenotype, whereas reciprocally repression of EFA6B promotes the mesenchymal phenotype, suggesting 
that EFA6B might regulate the epithelial-to-mesenchymal transition. TGFß is a major inducer of EMT during mammary gland morphogenesis and breast cancer progression (21) (22) (23) . TGFß induces early on the disassembly of the TJ to which the TGFß receptor (TGFßR) is physically associated through the polarity protein Par6 and occludin (24) (25) (26) (27) . When MCF7 cells were exposed to TGFß they downregulated the expression of E-cadherin and occludin, without affecting the endogenous EFA6B (Fig. 5A-B) . This was accompanied by a major change in cell morphology with the apparition of stress fibers and an elongated cell shape (Fig. 5C ). In contrast, MCF7-EFA6Bvsvg cells did not respond to TGFß treatment (Fig. 5A, C) . The expression of EFA6Bvsvg did not alter the levels of expression of TGFßR, thus the inhibitory effect of EFA6Bvsvg was not due to a decrease in the expression of TGFßR (data not shown).
The inhibitory effect of EFA6B was totally blocked upon co-expression of the dominant negative Arf6T27N-GFP (Fig. 5D ). Note that in those cells, as in MCF7 cells expressing Arf6T27N-GFP (data not shown), stress fibers were no longer observed even upon TGFß treatment. Nevertheless, the change in morphology and drop of E-cadherin expression were clearly apparent indicating that Arf6 activation is required to hamper the TGFß-induced EMT.
To assess whether this inhibitory effect was cell-specific we analyzed the non-mammary epithelial MDCK cell line. Like in MCF7 cells, in MDCK cells over-expressing EFA6Bvsvg the morphological changes and the decrease in the levels of E-cadherin and occludin in response to TGFß were totally blocked ( Supplementary Fig. S4 ).
Induction of EMT by TGFß is believed to take place through the activation of the canonical SMAD pathway which transduces gene expression program, and non-canonical pathways responsible for the rapid morphological changes including the Par6, PI3K and ERK pathways (23, 28) . We observed a steady increase in Smad2 phosphorylation in both MCF7 ( Fig. 5E) . TGFß induces the disassembly of the TJ by downregulating the levels of RhoA through Par6 and the ubiquitin-ligase Smurf1 (26) . Similarly to previous reports (29, 30), we found a transient but reproducible decrease in the levels of RhoA after 30min exposure to TGFß, which was comparable in both cell lines indicating that EFA6Bvsvg did not act through RhoA downregulation (Fig. 5E ). MCF7 cells carry an activating mutation of the PIK3CA leading to a constitutive phosphorylation of its downstream effector Akt (31, 32) .
This constitutive phosphoryaltion was unaffected by EFA6Bvsvg expression and we could not detect further phosphorylation upon TGFß treatment in either cell lines. Similarly, ERK1/2 phosphorylation was not increased by TGFß in MCF7 and MCF7EFA7Bvsvg cell lines (data not shown). Collectively, our data indicate that EFA6Bvsvg inhibits the TGFß-induced EMT through a yet unidentified mechanism.
EFA6B/PSD4 mRNA expression in breast cancer
The fact that EFA6B regulates the TJ assembly, apico-basal polarity and inhibits the TGFß-induced EMT led us to determine whether EFA6B might act as an antagonist to mammary tumoral progression in vivo. A recent transcriptomic analysis revealed the existence of a new subtype of BC called claudin-low (Cld-low) characterized by the loss of expression of the TJ components (2). Thus, we postulated that loss of EFA6B expression could contribute to the downregulation of the TJ during tumoral progression. Analysis of EFA6B mutations and copy number alterations from the cBioPortal website (33) showed a very low alteration rate (0.2%) in BC (Supplementary Fig. S5 ). Then, we analyzed the mRNA expression level of EFA6B/PSD4 in our collection of 43 human mammary cell lines previously profiled using DNA microarrays and of which 14 are characterized as Cld-low. EFA6B/PSD4 expression was lower in Cld-low cell lines than in non Cld-low cell lines (p<0.001, Student's t test; Fig.   6A ). Subsequently, we measured the expression levels of EFA6B/PSD4 in our large data set Table S1 ). From this cohort, a total of 500 tumors showed a two-fold or greater upregulation and 281 showed a two-fold or greater downregulation of EFA6B/PSD4, using normal breast tissue as the standard. Correlation analysis between EFA6B/PSD4 expression and histo-clinical features of tumors (Table 1) showed that EFA6B/PSD4 downregulation was associated (Fisher's exact test) with higher grade (p<0.001), higher frequency of ER-negative status (p<0.001), PR-negative status (p<0.001), triple-negative status (p<0.001), and more frequently basal (p<0.001) and Cld-low subtypes (p<0.001). Correlation also existed with disease-free survival (DFS) within the 2930 non-stage IV patients with follow-up available. A total of 1056 patients experienced a disease event, and 1874 remained disease-free after a median follow-up of 82 months. The 5-year metastasis-free survival (MFS) was 67% (95CI, 65-69%) for the whole population, and 54%, 67% and 76% in cases of downregulation, no deregulation and upregulation respectively (Fig.   6B) . Importantly, for all of the histo-clinical correlations described above, a continuum existed from downregulated to neutral to upregulated levels of EFA6B/PSD4 (Table 1 ).
In agreement with the survival data, we found that tumors with EFA6B/PSD4 downregulation were more frequently classified "high risk" of relapse by two major prognostic GES, the Amsterdam 70-gene signature and the Oncotype Recurrence Score. Here too, a continuum was present between the three groups defined by EFA6B/PSD4 expression (downregulation, neutral and upregulation) and the above gene signatures (Table 1) .
We next analyzed correlations between expression levels of EFA6B/PSD4 and those of 20 genes involved in TJ or EMT. As shown by the correlation matrix (Fig. 6C) , EFA6B/PSD4 expression positively correlated with that of genes involved in TJ, including claudin genes, and negatively correlated with that of genes involved in EMT. Of note, the three other EFA6/PSD genes did not correlate with the "TJ" and "EMT" gene clusters. We 
EFA6B and claudin-3 immunostaining expression in BC
To extend the transcriptome analyses, we carried out IHC studies on human mammary tumor samples and assessed the protein levels of EFA6B in relation to the subtype and prognosis.
We analyzed a collection 412 human primary invasive breast adenocarcinoma spotted onto a tissue microarray (TMA). The Cld-low subtype has only been defined by gene profiling, nevertheless claudin-3 appears to be one of the most significantly gene affected in this subset (2, 34) , so we quantified the levels of claudin-3 protein by IHC as a marker for the Cld-low subtype. We found a positive correlation between the presence of a triple-negative IHC for ER, PR and HER2 and low expression of both EFA6B and claudin-3 proteins in primary breast tumors (Fig. 6D) . Moreover, in tumors with a low expression of EFA6B, a low claudin-3 expression was concomitantly noted (Fig. 6D) . Finally, patients with low levels of EFA6B expression correlated significantly with a lower DFS expressed as the cumulative incidence of relapse (Fig. 6E) . Together with our transcriptomic analyses these data showed that EFA6B is lost in aggressive mammary tumors downregulated in TJ. We have provided evidence that the TJ regulator EFA6B acts as an antagonist to human BC development. In vitro, we have identified two biological processes regulated by EFA6B through which it might hamper or even revert BC progression: EFA6B inhibits the TGFß-induced EMT, and EFA6B increases the formation and fusion of VACs to promote epithelial apico-basal polarity of mammary acinis. In vivo, BC analyses show that loss of expression of EFA6B is a marker of poor prognosis and associated with the TNBC and Cldlow subtypes.
Based on these results and previous observations from us and others, we propose that 
formation of VACs and lumens. The EFA6/Arf6 complex is known to control cell surface transport, therefore it is possible that EFA6B over-expression stimulates the formation of endocytic vesicles from the basal surface of the plasma membrane to form VACs onto which EFA6B is localized, and then helps their subsequent fusion at cell-cell contacts to generate the lumens. Since the newly-formed lumens are delineated by TJs, EF6AB might also help form the lumen by strengthening its surrounding TJ, which have independently been shown to promote lumen formation (39).
In addition, the levels of expression of EFA6B determined the epithelial-mesenchymal morphological status of MCF7 cell aggregates, which indicated that EFA6B might control EMT. This is of primary importance since EMT has been largely implicated in CAN-14-0298 lower DFS. The transcriptomic analysis showed that tumors with low EFA6B expression were more frequently of the Cld-low subtype. This BC subtype is also defined by transcriptomic signatures associated with EMT and CSC, and a poor prognosis. Thus, collectively our transcriptomic, IHC and in vitro data all support a model whereby the loss of EFA6B might participate in the initiation or maintenance of the TJ-downregulated Cld-low subtype. In any case, independent of a possible role of EFA6B on the subtype orientation, it is striking that the same biological changes associated with EFA6B downregulation in human BC and the ones induced by a decrease in EFA6B levels in cell culture -namely loss of TJ and apico-basal polarity, increased EMT, stromal and CSC signatures-are all found in BC tumoral progression.
In summary, EFA6B appears as a potential tumor antagonist whose downregulation may trigger the progression towards the Cld-low subtype. Inhibition of the mechanisms that downregulate EFA6B levels may offer a much needed therapeutic option. 
